From left: Lawrence Cowan, Scotland Manager for Breast Cancer Now, Jen Hardy, Perjeta Now campaigner, and Donald Cameron MSP.
‘Women in Scotland should be able to access the life-extending breast cancer drug Perjeta, Highlands and Islands MSP Donald Cameron has argued. Donald Cameron joined breast cancer patient and Perjeta Now campaigner Jen Hardy at Holyrood to support the charity’s petition calling for the manufacturer Roche, the Scottish Government and the Scottish Medicines Consortium (SMC) to make Perjeta routinely available on the NHS in Scotland. Perjeta, taken in combination with Herceptin (trastuzumab) and docetaxel, a chemotherapy drug, is a first-line treatment for patients with HER2-positive metastatic breast cancer. It gives patients with incurable breast cancer nearly 16 additional months of good-quality life, on average, compared to the alternative treatment of trastuzumab and docetaxel alone.
While it has been the standard of care in England for more than four years, Perjeta has been rejected three times by the SMC as it is not considered cost-effective.
Leggete l'articolo completo e molti altri in questo numero di
The Oban Times & Lochaber Times
Opzioni di acquisto di seguito
Se il problema è vostro,
Accesso per leggere subito l'articolo completo.
Singolo numero digitale
21st June 2018
 
Questo numero e altri numeri arretrati non sono inclusi in un nuovo
abbonamento. Gli abbonamenti comprendono l'ultimo numero regolare e i nuovi numeri pubblicati durante l'abbonamento. The Oban Times & Lochaber Times
Abbonamento digitale di 6 mesi
€28,99
fatturati due volte l'anno
Abbonamento digitale annuale
€51,99
fatturati annualmente